Profile data is unavailable for this security.
About the company
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
- Revenue in USD (TTM)9.98m
- Net income in USD-154.08m
- Incorporated1983
- Employees160.00
- LocationCelldex Therapeutics Inc53 Frontage Road, Suite 220HAMPTON 08827United StatesUSA
- Phone+1 (908) 200-7500
- Fax+1 (302) 655-5049
- Websitehttps://celldex.com/